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Abstract. 36 
Purpose 37 
To describe a survey of the use of ocriplasmin by members of the British & Eire Association 38 
of Vitreo-Retinal Surgeons (BEAVRS) for Vitreo-Macular Traction (VMT) and Full Thickness 39 
Macular Hole (FTMH) and compare it to published MIVI-TRUST trial data. 40 
 41 
Methods 42 
All 173 BEAVRS members were contacted by email in October 2014 requesting data on all 43 
cases treated with ocriplasmin up to that date.  The total number of cases, FTMH closure 44 
rate, VMT release rate and the frequency of adverse events were recorded.  Results were 45 
compared to trial data. 46 
 3 
 47 
Results 48 
48 members responded reporting results from 241 eyes.  The respective BEAVRS and MIVI-49 
TRUST trial closure rates for small FTMHs were 42.1% and 58.3% (p=0.09) and for medium 50 
FTMH 12.7% and 36.7% (p=0.01). The respective VMT release rates were 34.1% and 37.4% 51 
(p=NS). Retinal detachment was observed in 3.3% of the BEAVRS cohort compared with 52 
0.4% in MIVI-TRUST.  Reduction in visual acuity to < 6/60 was observed in 5.8% of the 53 
BEAVRS cohort and 0.6% in MIVI-TRUST. Other complications not reported in the MIVI-54 
TRUST trial included an increase in FTMH basal diameter following unsuccessful ocriplasmin 55 
use in 46.9% of BEAVRS cases and zonular instability at the time of subsequent 56 
phacoemulsification in 2.4%.   57 
 58 
Conclusion 59 
Macular hole closure rates were lower in the BEAVRS survey than published in the MIVI-60 
TRUST trial data.  The incidence of adverse events was greater than previously reported.  61 
The reasons for these disparities are unknown but could include positive reporting bias 62 
inherent to retrospective surveys, treatment and population differences.  63 
 64 
 65 
Introduction 66 
Ocriplasmin is a first in class agent licensed within Europe in January 2013 for the 67 
pharmacological treatment of Vitreo Macular Traction (VMT) including that associated with 68 
full thickness macular holes (FTMH).   69 
 4 
 70 
The efficacy and side effect profile of ocriplasmin had been demonstrated in the 71 
Microplasmin for Intravitreous Injection — Traction Release without Surgical Treatment 72 
(MIVI-TRUST) pivotal trials (TG-MV-006 and TG-MV-007) reported in August 2012. 1 The 73 
authors concluded that ‘Intravitreal injection of ocriplasmin was superior to injection of 74 
placebo in altering the vitreoretinal interface of affected eyes, although it was accompanied 75 
by some, mainly transient, ocular adverse events.’ 1 Separate analysis of the safety data 76 
concluded “Ocriplasmin seems to be generally safe and well tolerated” 2. A subsequent 77 
publication performed a sub group analysis of the MIVI-TRUST data in which macular holes 78 
were divided into small and medium sized holes, that is those with an internal diameter or 79 
<250 microns or between 250 and 400 microns respectively. 3 Based upon these data 80 
ocriplasmin was recommended in October 2013 by the National Institute for Health and 81 
Care Excellence (NICE) for use within the NHS in England. Prior to this recommendation the 82 
post licensing use of ocriplasmin by BEAVRS members was limited to the minority private 83 
healthcare sector.    84 
 85 
Anecdotal reports of adverse events combined with early reports in the literature of 86 
previously unreported side effects, such as enlargement of the macular hole, zonular 87 
instability, and localised non-rhegmatogenous retinal detachment 4,5,6 prompted this survey 88 
of all BEAVRS members. The aim of this study was to ascertain the effectiveness of 89 
ocriplasmin and the incidence of adverse events in normal clinical practice.  To date no 90 
systematic national post marketing surveillance studies have been reported.   91 
 92 
 5 
Methods 93 
All 173 BEAVRS members (including 120 consultants) with a registered email address were 94 
contacted electronically in October 2014.  They were asked to report all cases of 95 
vitreomacular traction (VMT) with or without full thickness macular holes (FTMH) that they 96 
had treated with ocriplasmin.  Members were requested to complete a simple spreadsheet 97 
(Table 1).  The dataset included the total number of cases they had treated with 98 
ocriplasmin, the case mix divided into small FTMH (<250microns), medium FTMH (>250 and 99 
<400 microns) or pure VMT without FTMH, and the proportion with a successful anatomical 100 
outcome (i.e. closure of FTMH or release of VMT).  Adverse events surveyed included 101 
reduction in visual acuity to less than 6/60 Snellen, severe photopsia, photophobia, 102 
dyschromatopsia*, pain, retinal tear and/or retinal detachment, changes in the outer 103 
segment ellipsoid layer on optical coherence tomography*, electro retinogram changes*, 104 
increase in measured macular hole basal diameter*, zonular instability during subsequent 105 
cataract surgery* and subsequent failure of macular hole surgery*.  Items marked with an 106 
asterisk were not reported in the MIVI-TRUST publications.  107 
 108 
A second email was sent in January 2015 to collect additional cases and remind contributors 109 
of the importance of including data on all cases treated, without selection. Chi squared tests 110 
for differences in proportion were employed. 111 
 112 
Results 113 
Forty-one members responded to the survey that they had used ocriplasmin, in addition, 7 114 
members responded that they had not used ocriplasmin (even though this was not an 115 
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option in the survey) representing an overall response rate from consultant members of 116 
40%.  In the UK non-consultants would be unlikely to use ocriplasmin without consultant 117 
supervision, in addition at the time of surveying many consultant BEAVRS had not used 118 
ocriplasmin but the exact number is unknown as the survey did not ask this. However, at the 119 
BEAVRS meeting in 2014 there was an ‘ask the audience’ question about the preferred 120 
treatment option for a patient with a small FTMH - 66% voted surgery, 8% voted ocriplasmin 121 
and 26% voted observation, suggesting a low usage of ocriplasmin by BEAVRS at the time, 122 
consistent with the survey results. A total of 241 eyes were reported to have been injected 123 
with ocriplasmin.  The distribution of cases is shown in Table 2.   The respective BEAVRS and 124 
MIVI-TRUST closure rates of small FTMHs were 42.1% and 58.3% (p=0.09) and for medium 125 
sized FTMH 12.7% and 36.7% (p=0.01).  The outcomes for resolution of VMT were similar to 126 
the MIVI-TRUST findings with successful resolution of VMT in 34.1% & 37.4% respectively.   127 
A summary of the BEAVRS results with the percentages of each outcome relative to the 128 
total number of BEAVRS cases and the equivalent MIVI-TRUST percentage results for 129 
comparison are shown in Table 2.  Profound drop in vision to <6/60 was reported in 5.8% of 130 
cases, with one case falling temporarily to perception of light only (PL) for 24 hours. 11.6% 131 
of patients in the BEAVRS cohort experienced severe photopsia. Photopsia was described by 132 
some patients as like a ‘snow storm’ or a ‘poorly tuned TV’ and by others as like a ‘New 133 
Year’s Eve firework display’. Dyschromatopsia (mainly yellowing or dimming of vision) was 134 
reported in 6.2% of BEAVRS ocriplasmin cases.  Changes in the outer segment ellipsoid layer 135 
on OCT were identified in 10.4%. Ocriplasmin treatment of FTMH failed in 81/112 cases 136 
(72%); in these failed cases widening of the macular hole basal diameter on OCT scanning 137 
was reported in 46.9% (Figure 1). In one case sub-retinal fluid / lucency was identified in a 138 
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region distal to the MH around the optic nerve, including on the nasal side of the nerve 139 
(Figure 2).  140 
ERG changes were reported in six cases, however ERGs were only performed in some of the 141 
cases that reported marked visual loss. The reported ERG changes consisted of a marked 142 
reduction in a and b wave amplitudes and loss of oscillatory potentials suggesting 143 
widespread retinal dysfunction in all cases reported (Figure 3). We have no detailed data on 144 
how rapidly the ERG changes developed or the speed of recovery other than to say that the 145 
effect was prominent enough to be detected between two and three weeks after the 146 
ocriplasmin injection and in a few cases a relative suppression of the waveforms (compared 147 
to the untreated eye) was still present as far as 12 months after the ocriplasmin injection. 148 
 149 
Zonular dialysis was reported in four cases following ocriplasmin.  Two cases occurred at the 150 
time of combined phacoemulsification + lens implant + pars plana vitrectomy surgery for 151 
macular holes that had failed to respond to ocriplasmin treatment. The vitrectomy and 152 
phacoemulsification surgery in each case was reported as uneventful, however partial 153 
zonular dialysis occurred in one case during intraocular lens injection into the capsular bag.  154 
In the second case complete zonular rupture occurred during lens injection necessitating 155 
complete removal of the lens and capsular bag and insertion of an iris clip lens. The third 156 
case occurred during cataract surgery performed several months after a vitrectomy and gas 157 
repair of a retinal detachment subsequent to ocriplasmin injection.  In this case the zonules 158 
appeared to be absent in one quadrant at the beginning of the phacoemulsification. 159 
Phacodonesis had not been noted preoperatively. The fourth case occurred during the 160 
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irrigation / aspiration step of cataract surgery performed 12 months after vitrectomy 161 
performed for persistent VMT following ocriplasmin. 162 
 163 
Retinal detachment was found in 8 out of 241 (3.3%) cases reported.  There were no post 164 
injection retinal tears that did not progress to retinal detachment.    165 
Discussion 166 
The reported efficacy from the BEAVRS cohort was similar to that in the MIVI-TRUST phase 3 167 
trials for resolution of VMT.  However, the BEAVRS rate of closure of medium sized macular 168 
holes was significantly lower than published data (p=0.01).  Interestingly only 19 eyes in the 169 
MIVI-TRUST trials had medium sized FTMHs3 as compared to the larger sample size of 55 in 170 
the BEAVRS cohort.    171 
There was a higher than expected incidence of ocriplasmin related side effects reported in 172 
the BEAVRS survey.  These include changes in the ellipsoid zone, widening of the basal 173 
diameter of macular holes in which ocriplasmin treatment was unsuccessful, ERG 174 
abnormalities, the observation of localised non-rhegmatogenous retinal detachment, and 175 
the development of a rhegmatogenous retinal detachment in all cases where a post 176 
ocriplasmin retinal tear occurred. Grouped together these observations indicate ocriplasmin 177 
has a more widespread action than the target vitreoretinal interface, and are suggestive of 178 
enzyme action both within the retina and the sub-retinal space, rather than just at the 179 
target vitreo-retinal interface.  Muller glial cell disruption and subsequent recovery (being 180 
the only cell type capable of regeneration within the retina) has been proposed as the basis 181 
for the electrophysiological changes8, as the ERG has been reported to recover over a period 182 
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of months following ocriplasmin injection.  Laminin and fibronectin are found in the inter-183 
photoreceptor matrix and contribute to retinal adhesion.  It is possible that ocriplasmin 184 
gains access to the sub-retinal space via the macular hole, however with a molecular weight 185 
of 27.2 kDA it may be a small enough molecule to penetrate through the retina9. This trans-186 
retinal route would explain the observation of sub-retinal fluid around the optic nerve head 187 
including on the nasal side of the nerve7.  Further evidence for an adverse effect on retinal 188 
adhesion is that all eight of the BEAVRS cases with a retinal tear went on to develop a retinal 189 
detachment, whereas natural history studies of spontaneous posterior vitreous detachment 190 
suggest that only 30-50% of tears progress to retinal detachment10,11,12.  191 
The 46.9% incidence of widening of the FTMH basal diameter in failed ocriplasmin cases 192 
could have implications for visual outcomes, as increased basal diameter has previously 193 
been found to predict worse post-operative vision13, however, this was not found in the 194 
MIVI-TRUST trials where the acuity improvement in failed ocriplasmin eyes was the same as 195 
in placebo treated eyes. 14,15 There is uncertainty as to the cause of the observed widened 196 
basal diameter. It has been hypothesised that it may relate to the effect of increased 197 
vitreous traction on the hole during vitreolysis16. However the extent of widening does not 198 
vary with the degree of VMT release, which might have been expected if this was the cause 199 
and furthermore no increase in base diameter has been observed on intraoperative OCTs 200 
performed during surgery with either posterior hyaloid face separation or ILM peeling17,18.  201 
As with the other outer retinal changes associated with ocriplasmin, widening of the basal 202 
diameter is likely to be due to the proteolytic action of ocriplasmin on laminin in the 203 
interphotoreceptor matrix, which is partly responsible for adhesion of the retina to the RPE.   204 
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The observed 3.3% rate of retinal detachment in the BEAVRS cohort is much higher than the 205 
0.4% reported in the MIVI-TRUST report. A contributing factor to this discrepancy may be 206 
that the MIVI-TRUST phase 3 trials of ocriplasmin excluded patients with high myopia, one 207 
of the BEAVRS retinal detachments observed was in a patient with -9 dioptres of myopia.  208 
Exclusion of this individual results in a 2.9% rate of retinal detachment within the BEAVRS 209 
cohort compared to 0.4% in the published trials.   There are a number of other possible 210 
reasons for differences between the BEAVRS and MIVI-Trust data. The BEAVRS survey was 211 
retrospective and only 40% of consultant members contributed. It was performed 20 212 
months after European licensing and one year after recommendation by NICE for use on the 213 
NHS in England. The disparity in the reported results may arise from positive reporting bias 214 
by members who were disappointed with their results19. Similarly the respondents may 215 
have under-reported the total number of cases that they had performed.  Either error 216 
would lead to a higher proportion of complications or treatment failures.  Attempts were 217 
made to overcome these biases by reminding members to report all cases to maximise the 218 
denominator.  The BEAVRS results may also be subject to negative reporting bias with 219 
underestimation of the incidence of adverse events. Not all patients will have reported their 220 
symptoms or had them systematically recorded in the case notes.  In addition, only a few 221 
patients underwent ERG tests and not all clinicians would have rigorously measured MH 222 
basal diameter. This is however the largest reported cohort to date reporting real world 223 
outcomes of ocriplasmin.   224 
The reduced rate of closure in medium sized FTMH seen in the BEAVRS cohort could be 225 
explained by larger diameters within the BEAVRS medium sized FTMH group compared to 226 
the MIVI-TRUST cohort, but data to support or refute this are not available in either series. 227 
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Unlike the MIVI-TRUST trials, no eyes had ERMs pre-injection, as UK NICE guidelines exclude 228 
patients from treatment with ocriplasmin if there is any ERM present. 229 
Differences in injection technique could be important.  Ocriplasmin is stored at -25OC in an 230 
acidic pH. Once warmed and diluted with non-buffered saline, it starts to autolyse and has a 231 
rapid degradation profile within the eye. Differences in injection timing, and location within 232 
the vitreous cavity, could lead to variations in outcome.  It is recommended that ocriplasmin 233 
is given with a 13mm 30 gauge needle fully entered into the eye, but we have no knowledge 234 
of whether this was standard practice.  Too anterior a location may reduce efficacy at the 235 
vitreo-retinal interface, but increase the risk of zonule weakness.  Zonule dehiscence was 236 
not reported in the MIVI-TRUST data, and may be underestimated as zonular instability may 237 
not become apparent until cataract surgery is performed in larger numbers in the future. 238 
Other possible explanations for the variation in efficacy and side effects observed may exist 239 
in the biological action of ocriplasmin on the multiple forms of laminin present in the human 240 
retina20. These splice variants may be subject to genetic variation within and between 241 
different populations.  242 
 243 
In conclusion in this retrospective email survey of BEAVRS members we found both a higher 244 
incidence of adverse events after ocriplasmin, and lower success rates for macular hole 245 
closure, than described in the phase 3 trials. Further real world studies are recommended to 246 
further clarify the safety and efficacy of ocriplasmin. 247 
   248 
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Table 1. BEAVRS survey spreadsheet. 340 
Table  2. Results of BEAVRS survey with equivalent percentages from MIVI TRUST trials for 341 
comparison.  342 
 343 
Figure 1. Widening of the MH basal diameter following ocriplasmin. 344 
Before ocriplasmin.                           After ocriplasmin 345 
 346 
Figure 2. Sub-retinal fluid around the optic nerve, including on the nasal side of the nerve 347 
following ocriplasmin.  348 
 349 
Figure 3. ERG changes following ocriplasmin showing a marked reduction in dark adapted A 350 
and B wave amplitudes and loss of oscillatory potentials. 351 
